139 related articles for article (PubMed ID: 36650613)
1. The implications of airway anomalies on children with congenital heart disease and bronchiolitis.
Wang PY; Tseng WC; Wu ET; Lu FL; Chen SJ; Chiu SN; Wu MH; Wang JK; Wang CC
Pediatr Pulmonol; 2023 Apr; 58(4):1194-1200. PubMed ID: 36650613
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.
Ratti C; Greca AD; Bertoncelli D; Rubini M; Tchana B
Ital J Pediatr; 2023 Jan; 49(1):4. PubMed ID: 36631870
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
[TBL] [Abstract][Full Text] [Related]
4. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease.
Chang RK; Chen AY
Pediatr Cardiol; 2010 Jan; 31(1):90-5. PubMed ID: 19915892
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis.
Hervás D; Reina J; Yañez A; del Valle JM; Figuerola J; Hervás JA
Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1975-81. PubMed ID: 22240853
[TBL] [Abstract][Full Text] [Related]
6. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
7. RSV prophylaxis guideline changes and outcomes in children with congenital heart disease.
Walpert AS; Thomas ID; Lowe MC; Seckeler MD
Congenit Heart Dis; 2018 May; 13(3):428-431. PubMed ID: 29436781
[TBL] [Abstract][Full Text] [Related]
8. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database.
Law BJ; Wang EE; MacDonald N; McDonald J; Dobson S; Boucher F; Langley J; Robinson J; Mitchell I; Stephens D
Pediatrics; 1997 Mar; 99(3):E7. PubMed ID: 9099772
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses.
Friedman D; Fryzek J; Jiang X; Bloomfield A; Ambrose CS; Wong PC
PLoS One; 2017; 12(3):e0172512. PubMed ID: 28253361
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases.
Shmueli E; Goldberg O; Mei-Zahav M; Stafler P; Bar-On O; Levine H; Steuer G; Mussaffi H; Gendler Y; Blau H; Prais D
Pediatr Pulmonol; 2021 Jul; 56(7):2204-2211. PubMed ID: 33913611
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus-associated hospitalizations over three consecutive seasons in children with congenital heart disease.
Resch B; Kurath-Koller S; Hahn J; Raith W; Köstenberger M; Gamillscheg A
Eur J Clin Microbiol Infect Dis; 2016 Jul; 35(7):1165-9. PubMed ID: 27126331
[TBL] [Abstract][Full Text] [Related]
12. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations.
Rackham OJ; Thorburn K; Kerr SJ
Cardiol Young; 2005 Jun; 15(3):251-5. PubMed ID: 15865826
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of palivizumab in children with childhood interstitial lung disease: The French experience.
Drummond D; Thumerelle C; Reix P; Fayon M; Epaud R; Clement A; Mahloul M; Habouria D; Delacourt C; Hadchouel A
Pediatr Pulmonol; 2016 Jul; 51(7):688-95. PubMed ID: 26636747
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective.
Harris KC; Anis AH; Crosby MC; Cender LM; Potts JE; Human DG
Can J Cardiol; 2011; 27(4):523.e11-5. PubMed ID: 21664100
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease.
Alexander PM; Eastaugh L; Royle J; Daley AJ; Shekerdemian LS; Penny DJ
J Paediatr Child Health; 2012 May; 48(5):395-401. PubMed ID: 22720323
[TBL] [Abstract][Full Text] [Related]
16. Hospitalization for Respiratory Syncytial Virus Bronchiolitis in the Palivizumab Prophylaxis Era: Need for Reconsideration of Preventive Timing and Eligibility.
Oz-Alcalay L; Ashkenazi S; Glatman-Freedman A; Weisman-Demri S; Lowenthal A; Livni G
Isr Med Assoc J; 2019 Feb; 21(2):110-115. PubMed ID: 30772962
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study.
Ozyurt A; Narin N; Baykan A; Argun M; Pamukcu O; Zararsiz G; Sunkak S; Uzum K
Pediatr Pulmonol; 2015 Oct; 50(10):1025-32. PubMed ID: 25156973
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study.
Chiu SN; Wang JN; Fu YC; Chung HT; Chang LY; Wu MH; Hua YC; Lin MT; Lu CW; Chen CA; Wu JM; Wang JK
J Pediatr; 2018 Apr; 195():108-114.e1. PubMed ID: 29395174
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis.
Lewis L; Sinha I; Losty PD
Pediatr Pulmonol; 2022 Jan; 57(1):239-244. PubMed ID: 34617409
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
